| Description |
NAS-181 is a potent and selective rat 5-hydroxytryptamine1B (r5-HT1B) antagonist with an Ki value of 47 nM. NAS-181 increases the 5-HTP accumulation in rat brain regions[1].
|
| Related Catalog |
|
| In Vitro |
NAS-181 (compound (R)-25) (0-1000 nM) increases the K+-stimulated release of [3H]-5-HT from rat occipital cortical slices[1]. NAS-181 (3 mg/kg; s.c.) increases in the number of wet dog shakes in rats, and the effect is abolished by pretreatment of the rats with the tryptophan hydroxylase inhibitor p-chlorophenylalanine (pCPA) (200 mg/kg; i.p.)[1].
|
| In Vivo |
NAS-181 (20 mg/kg; s.c.) increases the 5-HTP accumulation in rat brain regions[1]. Animal Model: Rats[1] Dosage: 20 mg/kg Administration: S.c. Result: Significantly increased the 5-HTP accumulation in hypothalamus, hippocampus, frontal cortex, striatum, and the ratio 5-HIAA/5-HT in these brain regions was even more elevated (40−60%).
|
| References |
[1]. Berg S, et al. (R)-(+)-2-[[[3-(Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl] morpholine methanesulfonate: a new selective rat 5-hydroxytryptamine1B receptor antagonist. J Med Chem. 1998 May 21;41(11):1934-42.
|
